KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Cash from Financing Activities (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Cash from Financing Activities for 7 consecutive years, with -$12.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 263.37% to -$12.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$234.5 million through Dec 2025, up 30.53% year-over-year, with the annual reading at -$234.5 million for FY2025, 30.53% up from the prior year.
  • Cash from Financing Activities hit -$12.8 million in Q4 2025 for GoodRx Holdings, up from -$65.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of -$864000.0 in Q2 2024 to a low of -$172.1 million in Q3 2024.
  • Historically, Cash from Financing Activities has averaged -$44.5 million across 5 years, with a median of -$14.0 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: soared 97.19% in 2024 and later plummeted 5794.44% in 2025.
  • Year by year, Cash from Financing Activities stood at -$11.5 million in 2021, then soared by 58.26% to -$4.8 million in 2022, then plummeted by 2524.43% to -$125.6 million in 2023, then skyrocketed by 97.19% to -$3.5 million in 2024, then crashed by 263.37% to -$12.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for GDRX at -$12.8 million in Q4 2025, -$65.8 million in Q3 2025, and -$50.9 million in Q2 2025.